The expansion has doubled Cambrex’s footprint to 15,000 ft2, including an added 3500 ft2 of laboratory space.
Cambrex announced on Oct. 12, 2020 that it has completed the expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland.
According to a company press release, the expansion has doubled Cambrex’s footprint to 15,000 ft2, including an added 3500 ft2 of laboratory space. The expansion also featured the installation of an additional 13 fume cupboards to the laboratory, including three “walk-in” fume cupboards for increased capacity.
The site, which originally housed 50 employees, will now have room for up to 40 more scientists with the potential to expand in the future, the press release said.
“We have seen an increase in demand for services, and specifically for larger-scale crystallization projects, so this expansion increases our efficiency and ability to respond to these requests,” said Tom Loewald, CEO of Cambrex, in the press release. “The work we carry out at the Edinburgh site is one part of Cambrex’s integrated drug substance offering, and the investment increases our flexibility to work on projects at all stages of drug development.”
Source: Cambrex
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.